We are live on ! Find out more
SMMT icon

Summit Therapeutics
SMMT

37 hedge funds and large institutions have $42.9M invested in Summit Therapeutics in 2020 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

380% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 5

95% more funds holding

Funds holding: 19 → 37 (+18)

59% more capital invested

Capital invested by funds: $27M → $42.9M (+$15.9M)

8.77% more ownership

Funds ownership: 2.33% → 11.09% (+8.8%)

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

Holders
37
Holders Change
+18
Holders Change %
+94.74%
% of All Funds
0.65%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
24
Increased
4
Reduced
4
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
BlackRock
BlackRock
New York
+$3.09M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$2.33M
3
ECM
ExodusPoint Capital Management
New York
+$787K
4
Morgan Stanley
Morgan Stanley
New York
+$187K
5
Capstone Investment Advisors
Capstone Investment Advisors
New York
+$158K

Top Sellers

1
JP Morgan Chase
JP Morgan Chase
New York
-$4.54M
2
Renaissance Technologies
Renaissance Technologies
New York
-$213K
3
MFS
Mirabella Financial Services
United Kingdom
-$125K
4
HSBC Holdings
HSBC Holdings
United Kingdom
-$94K
5
HF
HRT Financial
New York
-$62K
Name Holding Trade Value Shares
Change 		Change in
Stake
PCH
1
Polar Capital Holdings
United Kingdom
$27.3M +$24.6M +5,800,000 New
BlackRock
2
BlackRock
New York
$3.43M +$3.09M +730,610 New
Vanguard Group
3
Vanguard Group
Pennsylvania
$2.58M +$2.33M +549,542 New
JP Morgan Chase
4
JP Morgan Chase
New York
$2.32M -$4.54M -1,071,121 -68%
Baillie Gifford & Co
5
Baillie Gifford & Co
United Kingdom
$1.75M – – –
Morgan Stanley
6
Morgan Stanley
New York
$1.19M +$187K +44,056 +21%
Renaissance Technologies
7
Renaissance Technologies
New York
$1.19M -$213K -50,200 -17%
ECM
8
ExodusPoint Capital Management
New York
$873K +$787K +185,844 New
UBS Group
9
UBS Group
Switzerland
$650K -$11.3K -2,673 -2%
BP
10
BBR Partners
New York
$235K – – –
Wells Fargo
11
Wells Fargo
California
$212K +$42.3K +10,000 +29%
Capstone Investment Advisors
12
Capstone Investment Advisors
New York
$175K +$158K +37,238 New
Goldman Sachs
13
Goldman Sachs
New York
$164K +$147K +34,809 New
Susquehanna International Group
14
Susquehanna International Group
Pennsylvania
$131K +$118K +27,886 New
Geode Capital Management
15
Geode Capital Management
Massachusetts
$91K – – –
IC
16
Inscription Capital
Texas
$80K – – –
Citadel Advisors
17
Citadel Advisors
Florida
$76K +$68.5K +16,170 New
Millennium Management
18
Millennium Management
New York
$74K +$67K +15,825 New
ProShare Advisors
19
ProShare Advisors
Maryland
$60K +$53.8K +12,696 New
Squarepoint
20
Squarepoint
New York
$60K +$54K +12,751 New
CAPTRUST Financial Advisors
21
CAPTRUST Financial Advisors
North Carolina
$52K – – –
VF
22
Virtu Financial
New York
$51K +$45.9K +10,835 New
Bank of America
23
Bank of America
North Carolina
$49K +$31.3K +7,390 +246%
H
24
HoyleCohen
California
$49K +$43.9K +10,359 New
TRCT
25
Tower Research Capital (TRC)
New York
$18K +$16K +3,783 New
1
2

SMMT Hedge Fund Activity: Q4 2020 in Review

37 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q4 2020, worth a combined $42.9M — up 59% from $27M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new SMMT positions and 5 closed out — a net gain of 19 holders — while 4 added to existing stakes and 4 trimmed.

The largest buyer was BlackRock, opening a new position worth an estimated $3.09M. The largest seller was JP Morgan Chase, cutting an estimated $4.54M.

  • 37 institutional investors held Summit Therapeutics (SMMT) as of Q4 2020, up from 19 in Q3 2020.
  • Funds reported $42.9M of Summit Therapeutics stock for Q4 2020, up 59% quarter-over-quarter.
  • 24 funds opened new Summit Therapeutics positions in Q4 2020 and 5 closed out, a net change of +19 holders.
  • The largest Summit Therapeutics buyer in Q4 2020 was BlackRock, an estimated $3.09M added.
  • The largest Summit Therapeutics seller in Q4 2020 was JP Morgan Chase, an estimated $4.54M sold.

Based on aggregated 13F filings for Q4 2020.